Trial-by-gene · MSI-H / dMMR

Active clinical trials enrolling MSI-H / dMMR solid tumors

Decision-support aid only — eligibility decisions must be confirmed against the actual trial protocol and the patient's medical record. Trial counts and statuses change daily; this page is for orientation, not adjudication.

MSI-H / dMMR pan-tumor trials focus on (1) neoadjuvant immunotherapy (NICHE-2 in CRC with stunning pCR rates), (2) immunotherapy + chemo or targeted therapy combinations in non-CRC settings, (3) post-checkpoint-inhibitor resistance, and (4) novel checkpoint molecules (LAG-3, TIM-3, TIGIT).

See the MSI-H cheat sheet.

Browse the live listing

Search ClinicalTrials.gov for actively recruiting solid-tumor trials with MSI-H / dMMR eligibility.

Open ClinicalTrials.gov listing

Source: ClinicalTrials.gov, US National Library of Medicine. Trial-listing data is in the public domain. Use of ClinicalTrials.gov data must comply with the NLM terms of use.

Representative trial phases and designs

Phase II, neoadjuvant CRC

Neoadjuvant nivolumab + ipilimumab in resectable dMMR CRC (NICHE-2 follow-on).

Phase III, 1L CRC

Nivolumab + ipilimumab vs pembrolizumab vs chemo + ICI in MSI-H mCRC (CheckMate 8HW and follow-ons).

Phase II, post-ICI resistance

LAG-3, TIM-3, TIGIT combinations after PD-1 progression in MSI-H solid tumors.

Frequently asked questions

Are Lynch syndrome carriers eligible for the same trials?
Generally yes — both germline (Lynch) and sporadic dMMR/MSI-H patients qualify for immunotherapy trials. Germline status sometimes affects prevention or surveillance trial eligibility separately.

Related